Amgen to Present at the Annual Oppenheimer Healthcare Conference
Amgen, a leading biotechnology company, is gearing up to present at the esteemed 35th Annual Oppenheimer Healthcare Life Sciences Conference. Narimon Honarpour, the senior vice president of global development at Amgen, will take center stage to discuss the company’s groundbreaking contributions and innovations in the life sciences.
Event Timing and Access
The presentation is scheduled for 11:20 a.m. ET on an upcoming Wednesday, with a simultaneous webcast accessible to a wide audience, including investors, news media personnel, and the general public. This approach enhances transparency and offers an opportunity for various stakeholders to gain insights into Amgen's latest developments.
Webcast Information
The webcast will not only cover this presentation but is also part of a series of selected talks that spotlight Amgen's advancements in medicine and biotechnology. Visitors to Amgen’s website will find detailed information regarding the presentation times, availability of the webcast, and additional links on their Investor Relations Events Calendar. Furthermore, the webcast will be archived for at least 90 days for those who wish to revisit the discussion.
About Amgen’s Innovations
Founded more than 40 years ago, Amgen has consistently been at the forefront of biotechnology, developing innovative therapies that have a profound impact on patients facing some of the world's most challenging health issues. The company's commitment to research and development drives its extensive pipeline, which includes treatments for cancer, cardiovascular disease, osteoporosis, inflammatory conditions, and rare diseases.
Recognition and Achievements
In recent years, Amgen has garnered respect and recognition within the industry. In 2024, the company was designated one of the “World’s Most Innovative Companies” by Fast Company and earned accolades as one of “America’s Best Large Employers” by Forbes. Such acknowledgments highlight Amgen’s leadership in making impactful contributions to healthcare.
Company Information
Amgen is not only a significant player in the biotechnology space but also an integral part of stock market indices such as the Dow Jones Industrial Average and the Nasdaq-100 Index. These memberships underline the company’s stature among the largest and most innovative non-financial firms listed on the stock market, emphasizing Amgen’s commitment to its stakeholders.
Stay Updated with Amgen
For those eager to learn more about Amgen, additional resources can be found on their corporate website. Interested individuals can explore updates on social media platforms like X, LinkedIn, Instagram, YouTube, and Threads, providing avenues for continued engagement with Amgen's latest initiatives and breakthroughs.
Contact Amgen
For media inquiries, Elissa Snook can be contacted at 609-251-1407, while Justin Claeys is available for investor relations at 805-313-9775. The open lines of communication ensure that both the public and investors remain informed about Amgen's endeavors.
Frequently Asked Questions
What is the purpose of Amgen's presentation at the conference?
The presentation aims to showcase Amgen’s latest innovations and advancements in the biopharmaceutical field to investors, media, and the public.
Who is presenting for Amgen at the conference?
Narimon Honarpour, the senior vice president of global development, will represent Amgen at the event.
Where can I watch the Amgen presentation?
The presentation will be available via a webcast on Amgen’s website, allowing access to a broader audience.
How long will the webcast be available for replay?
The archived webcast will be accessible for at least 90 days after the live event.
What kind of products does Amgen develop?
Amgen develops innovative medicines for various diseases, including cancer, heart disease, osteoporosis, inflammatory conditions, and rare diseases.
